Replies to post #305844 on NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

I believe TLD is the most important thing we'll see other than perhaps a partnership announcement this year. I'm not downplaying the SNO presentation, but it will fill in all the details of what's said in the TLD statement, but the TLD statement should get the investment community looking seriously at NWBO, I believe our price will be substantially higher once it's out. The SNO presentation may move it higher still, but not nearly as much percentage wise.

The terms of a partnership, if made, will establish an entirely different trading range as the partner will be bankrolling the advancement of the company's technology for the foreseeable future. In addition to going for the approval of DCVax-L in GBM, I believe a partnership will fund trials in DCVax-Direct in multiple cancers, as well as expanding the use of DCVax-L. I think we could see a partnership before the BLA is submitted.

Gary

[Dan88]

From sharpie510's post above:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158195899

It does seem the company has locked the data or is about to lock the data. Otherwise the unblinded data would not come out of the 13-year old trial like what Les said in the video aired on 8 September:

https://www.biztvclub.com/tv/search/video/6a63a72571be4a60f2ed7d4b91dcdcd8

Listen to 24-30 marks.

So it seems the company may acknowledge DL either via a news release or a filing or by Linda during her attendance the meeting on 12 Sep.

Or it may simply not acknowledge it publicly, and elect to only announce topline data.

But it does seem or is confirmed by Les topline data will be announced this month.

It also does make me wonder why Linda will be presenting on 12 Sep meeting without unblinded to data. Normally she would be quiet during such a special period awaiting topline data/unblind.